Has Anthony Botti, MD received payments from drug or device companies?

Yes. Drug and device makers reported $274,565 in general payments to Anthony Botti, MD across 693 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anthony Botti, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anthony Botti, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anthony Botti, MD

Hematology & Oncology · Livingston, NJNPI 1598787640

Payments from drug & device makers

$274,565in general payments, 2019–2025

Across 693 payments — averaging $396.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$96K
Novartis$87K
Dova Pharmaceuticals$53K
Sobi, Inc$27K
AstraZeneca$4K
Apellis Pharmaceuticals, Inc.$3K
plus $5K from 37 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	155	$96,230
Novartis	119	$86,814
Dova Pharmaceuticals	38	$52,501
Sobi, Inc	17	$26,581
AstraZeneca(2 entities)	48	$3,573
Apellis Pharmaceuticals, Inc.	8	$3,382
Amgen(2 entities)	97	$1,531
Takeda Pharmaceuticals U.S.A., Inc.	15	$593
Daiichi Sankyo Inc.	39	$515
Gilead	28	$427
Pharmacyclics LLC, An Abbvie Company	12	$388
Genentech USA, Inc.	16	$292
Lundbeck LLC	14	$225
Johnson & Johnson	13	$206
Lilly USA, LLC	4	$166
Eisai Inc.	3	$121
AMAG Pharmaceuticals, Inc.	6	$84
Merck	5	$82
EUSA Pharma (US) LLC	5	$76
Bristol Myers Squibb	5	$71
GSK	4	$71
Pfizer	5	$70
Octapharma USA, Inc.	3	$52
Biogen	3	$47
AbbVie	3	$43
Global Blood Therapeutics, Inc.	3	$42
E.r. Squibb & Sons, L.L.C.	3	$39
Invivyd Inc	2	$37
Astellas Pharma US Inc	2	$33
Rigel Pharmaceuticals, Inc.	2	$30
Sandoz	1	$27
Pharmacosmos Therapeutics Inc.	2	$25
Shire North American Group Inc	2	$25
Bayer	1	$23
Otsuka America Pharmaceutical, Inc.	2	$23
Radius Health, Inc.	1	$19
Biocon Biologics Inc	1	$18
Novo Nordisk	1	$17
Boehringer Ingelheim	1	$17
Teva Pharmaceuticals USA, Inc.	1	$13
Organon	1	$12
Seqirus USA Inc	1	$12
Amarin Pharma, Inc.	1	$12

How this compares

$274,565 in reported general payments places this provider in the 85th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$3,972,609

Medicare patients

1,083

Services billed

213,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Livingston

Linda DanieuLivingston$1.2M
David GallinsonLivingston$771K
Bruno FangEast Brunswick$8.5M
Charles FarberMorristown$4.6M
Rajat BannerjiNew Brunswick$3.3M
Eleonora TeplinskyParamus$2.6M
Mohamad CherryMorristown$1.9M
Evan NaylorManahawkin$1.3M
James OrsiniBelleville$1.3M
Eli KirshnerWestwood$1.2M

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →